COSCIENS Biopharma Inc. (CSCI)

NASDAQ: CSCI · Real-Time Price · USD
3.489
-0.079 (-2.21%)
At close: Jun 18, 2025, 4:00 PM
3.480
-0.009 (-0.26%)
After-hours: Jun 18, 2025, 4:00 PM EDT
-2.21%
Market Cap 11.09M
Revenue (ttm) 9.03M
Net Income (ttm) -17.56M
Shares Out 3.15M
EPS (ttm) -6.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,018
Open 3.570
Previous Close 3.568
Day's Range 3.320 - 3.580
52-Week Range 1.960 - 7.540
Beta 1.78
Analysts n/a
Price Target n/a
Earnings Date Aug 12, 2025

About CSCI

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 1996
Employees 40
Stock Exchange NASDAQ
Ticker Symbol CSCI
Full Company Profile

Financial Performance

In 2024, COSCIENS Biopharma's revenue was $9.59 million, an increase of 34.22% compared to the previous year's $7.14 million. Losses were -$15.31 million, 339.3% more than in 2023.

Financial numbers in USD Financial Statements

News

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversifie...

24 days ago - GlobeNewsWire

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; C...

5 weeks ago - GlobeNewsWire

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operat...

2 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a divers...

2 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diver...

3 months ago - Newsfile Corp

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

TORONTO, ONTARIO, March 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a divers...

3 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

Company leveraging core competencies to develop and commercialize  natural-based products to improve health and wellness

6 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- C...

7 months ago - GlobeNewsWire

COSCIENS Biopharma Announces Change to Board of Directors

TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializi...

9 months ago - GlobeNewsWire

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializi...

9 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializ...

9 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of mac...

10 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024

11 months ago - GlobeNewsWire